Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Divestments: 2010-2014

Historic Divestments for Arrowhead Pharmaceuticals (ARWR) over the last 3 years, with Mar 2014 value amounting to $10.5 million.

  • Arrowhead Pharmaceuticals' Divestments changed negligibly% to $10.5 million in Q1 2014 from the same period last year, while for Mar 2014 it was $42.1 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $487,593 for FY2010, which is N/A change from last year.
  • Latest data reveals that Arrowhead Pharmaceuticals reported Divestments of $10.5 million as of Q1 2014, which was down 0.00% from $10.5 million recorded in Q4 2013.
  • In the past 5 years, Arrowhead Pharmaceuticals' Divestments registered a high of $10.5 million during Q2 2011, and its lowest value of $57,593 during Q3 2010.
  • Over the past 3 years, Arrowhead Pharmaceuticals' median Divestments value was $10.5 million (recorded in 2014), while the average stood at $10.5 million.
  • Data for Arrowhead Pharmaceuticals' Divestments shows a peak YoY soared of 18,182.77% (in 2011) over the last 5 years.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Divestments (Quarterly) stood at $57,593 in 2010, then soared by 18,182.77% to $10.5 million in 2011, then remained steady at $10.5 million in 2012, then remained steady at $10.5 million in 2013, then remained steady at $10.5 million in 2014.
  • Its last three reported values are $10.5 million in Q1 2014, $10.5 million for Q4 2013, and $10.5 million during Q3 2013.